Michael Gelband’s Alnylam Pharmaceuticals ALNY Stock Holding History

Michael Gelband’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-30,823	Closed	-$14.1M	–	1501
2025 Q3	$14.1M	Buy	+30,823	New	+$12.6M	0.14%	131
2024 Q4	–	Sell	-18,988	Closed	-$5.22M	–	1473
2024 Q3	$5.22M	Buy	+18,988	New	+$4.94M	0.03%	410
2024 Q2	–	Sell	-18,658	Closed	-$2.79M	–	1488
2024 Q1	$2.79M	Buy	+18,658	New	+$3.11M	0.02%	584
2023 Q2	–	Sell	-13,953	Closed	-$2.79M	–	1822
2023 Q1	$2.79M	Buy	+13,953	New	+$2.93M	0.02%	747
2022 Q4	–	Sell	-3,122	Closed	-$625K	–	1606
2022 Q3	$625K	Sell	3,122 -7,541	-71%	-$1.44M	0.01%	1287
2022 Q2	$1.55M	Buy	+10,663	New	+$1.51M	0.02%	895
2022 Q1	–	Sell	-5,745	Closed	-$974K	–	2152
2021 Q4	$974K	Buy	+5,745	New	+$1.07M	0.01%	1085
2021 Q3	–	Sell	-23,458	Closed	-$3.98M	–	2063
2021 Q2	$3.98M	Buy	23,458 +696	+3%	+$102K	0.04%	435
2021 Q1	$3.21M	Buy	22,762 +19,661	+634%	+$2.96M	0.05%	403
2020 Q4	$403K	Buy	+3,101	New	+$414K	﹤0.01%	1378
2020 Q1	–	Sell	-23,876	Closed	-$2.75M	–	1053
2019 Q4	$2.75M	Buy	+23,876	New	+$2.38M	0.05%	268

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Michael Gelband's ALNY Position: Q4 2025 in Review

Michael Gelband sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 30,823 shares — an estimated $14.1M sold.

Michael Gelband first reported a position in ALNY in Q4 2019 and held it in 11 quarters. The position peaked at $14.1M in Q3 2025. 851 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

Michael Gelband reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Michael Gelband sold 30,823 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $14.1M.
Michael Gelband first reported a position in Alnylam Pharmaceuticals in Q4 2019 and held it in 11 quarters.
Michael Gelband's Alnylam Pharmaceuticals position peaked at $14.1M in Q3 2025.
851 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on ExodusPoint Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.